Is Gufic Biosciences the Best Stock in Its Sector? A Look at the Numbers
- September 25, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Gufic Biosciences CMP Rs 423 (25 Sep 2026). Market cap Rs 4,224 Cr. ROE 9.66%. P/E 57.55x versus Industry P/E 38.64x.
Quick Answer
Gufic Biosciences is one of the names investors compare when screening the Healthcare sector, built on a 9.66% return on equity and a P/E of 57.55x against an Industry P/E of 38.64x. Whether Gufic Biosciences is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Gufic Biosciences the best stock in its sector? The stock trades on the NSE at Rs 423 as of 25 September 2026, within its 52-week range of Rs 268.00 to Rs 467.80. Gufic Biosciences Ltd manufactures injectable and critical care pharmaceutical formulations.
Gufic Biosciences sits in the Healthcare sector, and its 9.66% ROE and 57.55x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Gufic Biosciences
Gufic Biosciences Ltd manufactures injectable and critical care pharmaceutical formulations. It manufactures injectable and critical care pharmaceutical formulations. At a market capitalisation of Rs 4,224 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Gufic Biosciences the Best Stock in Its Sector?
Gufic Biosciences makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 9.66% ROE with a 57.55x P/E against the sector’s 38.64x Industry P/E. Gufic Biosciences’ 57.55x P/E is above the 38.64x Industry P/E, a premium built on its injectable and critical care formulations niche, though its 9.66% ROE is modest relative to the multiple.
| Metric | Gufic Biosciences |
|---|---|
| CMP (NSE) | Rs 423.30 |
| 52-Week High / Low | Rs 467.80 / Rs 268.00 |
| Market Cap | Rs 4,224 Cr |
| P/E (TTM) vs Industry P/E | 57.55x vs 38.64x |
| P/B | 6.35 |
| ROE | 9.66% |
| EPS (TTM) | Rs 7.32 |
| Dividend Yield | 0.02% |
| Debt to Equity | 0.61 |
Compare Gufic Biosciences Against Other Healthcare Sector Stocks
How Gufic Biosciences Compares Against Its Healthcare Sector Peers
The table below sets Gufic Biosciences against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Gufic Biosciences | 4,224 | 57.55 | 9.66% | 0.61 |
| GPT Healthcare | 1,321 | 27.95 | 15.67% | 0.34 |
| Gaudium IVF and Women Health | 844 | 36.48 | 16.06% | 0.16 |
| Peer average (2 companies) | – | 32.21 | 15.86% | 0.25 |
Against this peer set, Gufic Biosciences’s 9.66% ROE is below the 15.86% peer average, and its P/E of 57.55x runs above the peer average of 32.21x. Gufic Biosciences’ 57.55x P/E is above the 38.64x Industry P/E, a premium built on its injectable and critical care formulations niche, though its 9.66% ROE is modest relative to the multiple.
What Makes Gufic Biosciences Worth Watching in Healthcare
- Solid ROE: A 9.66% ROE is a reasonable figure for an injectable and critical care pharma manufacturer.
- Injectable and critical care formulations niche: Manufacturing injectable and critical care pharmaceutical formulations gives Gufic Biosciences a specialised, higher-barrier segment of pharma manufacturing.
- Above Industry P/E: A 57.55x P/E against a 38.64x Industry P/E reflects a premium relative to the broader Healthcare sector.
Gufic Biosciences Valuation: Is It Justified?
Gufic Biosciences’ 57.55x P/E is above the 38.64x Industry P/E, a premium built on its injectable and critical care formulations niche, though its 9.66% ROE is modest relative to the multiple. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is GM Breweries the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Gufic Biosciences and other Healthcare sector stocks.
How to Track Gufic Biosciences Before You Invest
Before deciding whether Gufic Biosciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Gufic Biosciences to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Gufic Biosciences earns a place in the best stock in its sector conversation on the strength of a 9.66% ROE and a P/E of 57.55x against a 38.64x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Gufic Biosciences the best stock in its sector?
Ans. Gufic Biosciences has a 9.66% ROE and trades at 57.55x P/E against a 38.64x Industry P/E, and compares below the peer average ROE of 15.86% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Gufic Biosciences?
Ans. Gufic Biosciences was trading at Rs 423.30 on the NSE as of 25 September 2026, within its 52-week range of Rs 268.00 to Rs 467.80.
What sector does Gufic Biosciences belong to?
Ans. Gufic Biosciences is classified under the Healthcare sector on Univest.
How does Gufic Biosciences compare to its sector peers on P/E?
Ans. Gufic Biosciences’s P/E of 57.55x is above the 32.21x average of the 2 named peers compared in this article.
What is Gufic Biosciences’s return on equity?
Ans. Gufic Biosciences reported a return on equity of 9.66%, which is below the 15.86% average of its named peers in this comparison.
Should I invest in Gufic Biosciences based on its sector position?
Ans. Gufic Biosciences’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
